Keywords
Transdermal drug delivery system
Leishmania
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To identify studies that analyzed the use of different transdermal delivery systems, both for new substances with leishmanicidal potential and for drugs included in the therapeutic arsenal for the treatment of cutaneous leishmaniasis. Methods: To achieve this goal, the following steps were employed: theme identification, formulation of the guiding question, definition of descriptors and selection of databases, establishment of inclusion and exclusion criteria for the works, literature sampling, and pre-selection of works (reading abstracts and titles); reading of selected studies, and finally, interpretation of results. Results: As a result, 903 studies were found, with 305 using the descriptors "leishmaniasis" AND "drug delivery systems" and 598 with the descriptors "leishmaniasis" AND "transdermal administration". Among these, 820 were excluded after reading the titles and abstracts, and an additional 67 after full-text reading. After thorough analysis and reading, 16 studies were selected. Final considerations: The studies reviewed in this article demonstrate that transdermal delivery systems have shown promise and innovation in the treatment of cutaneous leishmaniasis.
References
ALISHAHI M, et al. Glucantime-loaded electrospun core-shell nanofibers composed of poly(ethylene oxide)/gelatin-poly(vinyl alcohol)/chitosan as dressing for cutaneous leishmaniasis. International Journal of Biological Macromolecules, 2020; 15(163): 288-297.
ASGARI Q, et al. Fabrication of amphotericin B-loaded electrospun core–shell nanofibers as a novel dressing for superficial mycoses and cutaneous leishmaniasis. International Journal of Pharmaceutics, 2021; 606: 120911.
BHOWMIK, D, et al. Recent Approaches in Transdermal Drug Delivery System. The Pharma Innovation Journal. J.,2013; 2(3): 99 – 108.
BOTELHO LLR, et al. O Método da Revisão Integrativa nos Estudos Organizacionais. Revista Eletrônica Gestão e Sociedade, 2011; 5(11): 121-136.
BRASIL. Ministério da Saúde. Casos de Leishmaniose Tegumentar. Brasil, Grandes Regiões e Unidades Federadas. 1990 a 2018. 2020a. Disponível em: https://www.saude.gov.br/images/pdf/2019/outubro/14/LT-Casos.pdf. Acesso em: 26 de julho, 2023.
BRASIL. MINISTÉRIO DA SAÚDE. Secretaria de Vigilância em Saúde. Nota Informativa nº 13/2020 – CGZV/DEIDT/SVS/MS. Brasília: Ministério da Saúde, 2020b. Disponível em: https://www.gov.br/saude/pt-br/media/pdf/2020/dezembro/17/notainformativamiltefosina.pdf. Acesso realizado em 23 de julho de 2023.
COELHO D, et al. Polyvinyl alcohol-based electrospun matrix as a delivery system for nanoemulsion containing chalcone against Leishmania (Leishmania) amazonensis, Colloids and Surfaces B: Bioint, 2021; 198: e111390.
COSTA AMB, et al. Sistema termossensível formado por poloxâmeros contendo carvacrol: um sistema carreador eficaz contra Leishmania amazonensis. Acta Tropica, 2023; 237: e106744.
DHIMAN S, et al. Transdermal patches: a recent approach to new drug delivery system. Inter. J. Pharm. Pharmaceut. Scien., 2011; 3(5): 26-34.
EBRAHIMISADR P, et al. Effect of Polyvinyl Alcohol (PVA) Containing Artemether in Treatment of Cutaneous Leishmaniasis Caused by Leishmania major in BALB/c Mice. Jundishapur Journal of Microbiology, 2014; 7(5): e9696.
FLETCHER RH, et al. Epidemiologia clínica: elementos essenciais. 3 ed. Porto Alegre: Artes Médicas, 1996; 281p.
HAMIDIAN H e TAVAKOLI T. Preparation of a new Fe 3 O 4 /starch- g -polyester nanocomposite hydrogel and a study on swelling and drug delivery properties. Carbohydrate Polymers, 2016; 144: 140–148.
HIGUITA-CASTRO J, et al. Development of a biocompatible polymeric chitosan system for the release of compounds with leishmanicidal activity. Materials & Design, 2021; 212: e110232.
KHAN AU, et al. Designing, Optimization and Characterization of Trifluralin Transfersomal Gel to Passively Target Cutaneous Leishmaniasis. Journal of Pharmaceutical Sciences, 2022 ; 111(6) : 1798-1811.
MALI AD, et al. An updated review on transdermal drug delivery systems. International Journal of Advanced Science and Research, 2015; 1(6): 244.
MENDES EV. As Redes de Atenção à Saúde. Ciênc. Saúd. Colet.,2010; 15(5): 2297-2305.
MENEZES J, et al. Advances in Development of New Treatment for Leishmaniasis. BioMed Research International, 2015; 1(11): e101155.
LANZA JS, et al. TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization. International Journal of Pharmaceutics, 2020; 30(586): e119390.
PEIXOTO JF, et al. Development of a microemulsion loaded with epoxy-α-lapachone against Leishmania (Leishmania) amazonensis murine infection. International Journal of Pharmaceutics, 2023; 636: e122864.
PEPPAS NA, et al. R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Advanced Materials, 2006;18(11): 1345-1360.
PEREZ AP, et al. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro. Colloids and Surfaces B: Biointerfaces, 2016; 139: 190–198.
PEZZINI BR, et al. Formas farmacêuticas sólidas orais de liberação prolongada: sistemas monolíticos e multiparticulados. Brazilian Journal of Pharmaceutical Sciences, 2007; 43(4): 491–502.
PINHEIRO IM, et al. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis. Experimental Parasitology, 2016; 164: 49–55.
SANTIAGO AS, et al. Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review. Research, Society and Development, 2021; 10(7): e29510716543.
SCHWARTZ J, et al. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation. European Journal of Pharmaceutical Sciences, 2014; 62: 309–316.
SHARMA A, et al. Transdermal drug delivery system: a review. International Journal of Research in Pharmaceutical and Biomedical, 2018; 7(7): 260-288.
SILVA MA, et al. Antileishmanial activity evaluation of a natural amide and its synthetic analogs against Leishmania (V.) braziliensis: an integrated approach in vitro and in silico. Parasitology Research., 2021; 120: 2199–2218.
SILVEIRA LMC e RIBEIRO VMB. Compliance with treatment groups: a teaching and learning arena for healthcare professionals and patients. Interface – Comunicação, Saúde, Educação, 2005; 9(16): 91-104.
TIWARI N, et al. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis. Mini-Reviews in Medicinal Chemistry, 2018; 18(1): 91–104.
ULIANA SRB, et al. Chemotherapy of leishmaniasis: present challenges. Parasitology, 2018; 145(4): 464-480.
VAN BOCXLAER K, et al. Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis. Pharmaceutics, 2021; 13(4): e516.
YADAV V. Transdermal drug delivery system: review. International Journal of Pharmaceutical Sciences and Research, 2012; 3(2): 376-382.
ZARE MR, et al. Dissolvable carboxymethyl cellulose/polyvinylpyrrolidone microneedle arrays for transdermal delivery of Amphotericin B to treat cutaneous leishmaniasis. International Journal of Biological Macromolecules, 2021; 182: 1310–1321.